JERUSALEM: BioLineRx, a biopharmaceutical development company, has selected New York-based agency KCSA Strategic Communications to manage its investor relations.
KCSA will be responsible for implementing a comprehensive IR communications campaign to build awareness of BioLineRx among the US investment community. Todd Fromer, managing partner at the agency, will lead the account.
In July, BioLineRx listed its shares on the NASDAQ Capital Market. The biopharma company develops products for central nervous system diseases, oncology, infectious diseases, cardiovascular, and autoimmune diseases.